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To investigate a multimodal, multiparametric perfusion MRI / 18F-fluoro-deoxyglucose-
(18F-FDG)-PET imaging protocol for monitoring regorafenib therapy effects on experimental
colorectal adenocarcinomas in rats with immunohistochemical validation.
Materials and Methods
Human colorectal adenocarcinoma xenografts (HT-29) were implanted subcutaneously
in n = 17 (n = 10 therapy group; n = 7 control group) female athymic nude rats (Hsd:RH-
Foxn1rnu). Animals were imaged at baseline and after a one-week daily treatment protocol
with regorafenib (10 mg/kg bodyweight) using a multimodal, multiparametric perfusion
MRI/18F-FDG-PET imaging protocol. In perfusion MRI, quantitative parameters of plasma
flow (PF, mL/100 mL/min), plasma volume (PV, %) and endothelial permeability-surface
area product (PS, mL/100 mL/min) were calculated. In 18F-FDG-PET, tumor-to-back-
ground-ratio (TTB) was calculated. Perfusion MRI parameters were correlated with TTB
and immunohistochemical assessments of tumor microvascular density (CD-31) and cell
proliferation (Ki-67).
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Results
Regorafenib significantly (p<0.01) suppressed PF (81.1±7.5 to 50.6±16.0 mL/100mL/min),
PV (12.1±3.6 to 7.5±1.6%) and PS (13.6±3.2 to 7.9±2.3 mL/100mL/min) as well as TTB
(3.4±0.6 to 1.9±1.1) between baseline and day 7. Immunohistochemistry revealed signifi-
cantly (p<0.03) lower tumor microvascular density (CD-31, 7.0±2.4 vs. 16.1±5.9) and tumor
cell proliferation (Ki-67, 434.0 ± 62.9 vs. 663.0 ± 98.3) in the therapy group. Perfusion MRI
parameters ΔPF, ΔPV and ΔPS showed strong and significant (r = 0.67-0.78; p<0.01)
correlations to the PET parameter ΔTTB and significant correlations (r = 0.57-0.67; p<0.03)
to immunohistochemical Ki-67 as well as to CD-31-stainings (r = 0.49-0.55; p<0.05).
Conclusions
Amultimodal, multiparametric perfusion MRI/PET imaging protocol allowed for non-inva-
sive monitoring of regorafenib therapy effects on experimental colorectal adenocarcinomas
in vivo with significant correlations between perfusion MRI parameters and 18F-FDG-PET
validated by immunohistochemistry.
Introduction
In recent years a broad range of novel molecular cancer therapeutics were introduced into clin-
ical use [1–3]. Among these are anti-angiogenic therapies, like tyrosine kinase inhibitors,
which have shown their effectiveness in the treatment of several malignancies including colo-
rectal cancer [4–6]. Regorafenib, an oral multi tyrosine kinase inhibitor, showed in vivo anti-
angiogenic and anti-proliferative effects in different experimental tumor models, such as breast
cancer, renal cell carcinoma and glioblastoma and has proven effectiveness in the clinical treat-
ment of metastatic colorectal cancer [7,8]. These new therapy regimes demonstrated significant
effects on tumor angiogenesis and tumor metabolism, but often only subtle effects on tumor
morphology, particularly in early stages of tumor treatment [9]. However, it has been shown,
that established methods of monitoring cytotoxic tumor therapies, such as morphology-based
Response Evaluation Criteria in Solid Tumors (RECIST) are not sufficiently sensitive for moni-
toring the early therapeutic effects of molecular anti-cancer agents to allow for a timely differ-
entiation of responders from non-responders [10,11].
Functional imaging techniques including perfusion magnetic resonance imaging (MRI)
and positron emission tomography (PET) can be applied for the assessment of physiological pro-
cesses in vivo such as tissue microcirculation or glucose metabolism [12–15]. In multiparametric
MRI protocols these functional surrogate markers of tumor metabolism are complementing
state-of-the-art high resolution imaging of tumor morphology adding valuable information for a
more comprehensive, non-invasive characterization of the tumor microenvironment [16,17].
Multiple experimental and clinical studies demonstrated the potential of contrast-enhanced per-
fusion MRI for the non-invasive assessment of anti-angiogenic treatment effects on several can-
cer entities as well as their potential applicability as non-invasive imaging biomarkers of therapy
response [18–21]. However, controversy still exists not only on standardized protocols of data
acquisition and analysis, but also with respect to the pathophysiologic correlate of altered tumor
microcirculation under molecular cancer therapy [22–25]. A multiparametric characterization of
treatment effects with the assessment of different aspects of tumor metabolism under therapy,
e.g. glucose metabolism quantified by 18F-FDG PET, is of particular interest not only to acquire a
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multi-facetted chart of treatment effects but also to reveal potential interdependencies between
the different acquired parameters of tumor pathophysiology. Multimodality hybrid imaging
protocols such as MRI/PET are able to assess a number of functional imaging parameters in a
one-stop-shop approach, including tumor perfusion and glucose metabolism, allowing for an
intraindividual comparison and validation of the parameters.
Therefore, the hypothesis of our study was that a multimodality, multiparametric imaging
protocol including perfusion MRI and 18F-FDG PET can be applied for monitoring the anti-
angiogenic and anti-proliferative effects of regorafenib on experimental colon carcinomas in
vivo. The purpose of our project was first, to investigate whether the acquired parameters of
tumor microcirculation and glucose metabolism can be applied as non-invasive imaging bio-
markers of therapy response, validated by immunohistochemistry, and second to evaluate a po-
tential biological relationship between tumor microcirculation and tumor glucose metabolism
by correlating the acquired parameters.
Materials and Methods
Animal model and experimental protocol
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was ap-
proved by the Government of Upper Bavaria Committee for Animal Research (Gz.55.2–1–54–
2532–33–10). Human colon cancer cells HT-29 (ATCC HTB- 38, Wesel, Germany) were dis-
solved in a total volume of 0.5 mL as a 1:1 mixture of phosphate buffered saline (PBS pH 7.4;
GIBCO Life Technologies, Darmstadt, Germany) and Matrigel (BD Biosciences, San Jose, CA)
and were injected subcutaneously into the left abdominal flank (2x106 cells per rat) of athymic
nude rats (n = 17; 7–8 weeks old, Harlan Laboratories Inc., Indianapolis, IN). Subcutaneous xe-
nografts were allowed to grow to a size of 800 mm3 assessed by daily caliper measurements in
three dimensions (a×b×c). Animals were randomly assigned to either the treatment (n = 10) or
to the control group (n = 7) and imaged using a multimodality imaging protocol including 18F-
FDG PET and subsequent perfusion MRI on day 0 and day 7. Animals were treated with the
multityrosine kinase inhibitor regorafenib (10 mg/kg bodyweight, Bayer Healthcare AG,
Leverkusen, Germany), or with volume-equivalent applications of the regorafenib solvent
(Cremophor/Ethanol) day 1 through day 6 via gastric gavage using a dedicated 16-gauge
curved buttoned cannula. Subsequent to imaging on day 7, animals were euthanized and
tumors were explanted, fixed in formalin for immunohistochemical work-up.
Multiparametric MRI protocol
Multiparametric MRI was performed at 3 Tesla on a clinical MRI scanner (Magnetom Verio,
Siemens Healthcare, Erlangen, Germany) with the rats in supine position, using a four-channel
small Flex Coil (Siemens Healthcare, Erlangen, Germany). For the morphologic and anatomic
assessment of tumor growth T2-weighted MR images were acquired using a 2D Turbo Spin
Echo sequence (TR/TE: 5470/91ms) with 0.3x0.3 mm in-plane resolution resulting in a matrix
size of 192x192 and slice thickness of 1.5 mm. Additionally a fast view-sharing gradient-re-
called echo time-resolved angiography with stochastic trajectories (TWIST) sequence [26] was
started for acquisition of the pre-contrast baseline and subsequent contrast medium bolus
tracking with high temporal resolution and acquisition of n = 300 datasets, resulting in an ac-
quisition time of 10:13 min (Sequence details: TR/TE: 6.34/2.11 ms; flip angle 40°; matrix size
128x128; field of view 50 x 50 mm2; spatial resolution, 0.39 x 0.39 x 3.0 mm3). For standardized
contrast media administration an automated bolus of 0.1mmol/kg body-weight of gadobutrol
(Gadovist, Bayer Healthcare, Leverkusen, Germany) followed by a saline bolus of 0.5 mL was
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applied using a dedicated small animal contrast media injection system (Harvard Apparatus
PHD 2000 Infuse/Withdraw, Holliston, MA).
MRI data processing and kinetic analysis
Data sets were post-processed on an external workstation with PMI software (Platform for Re-
search in Medical Imaging version 0.4) [27], written in house in IDL 8.3 (ITT Visual Informa-
tion Solutions, Boulder, CO). A blood region of interest (ROI) was drawn into the lumen of the
intrahepatic part of the inferior vena cava to assess an arterial input function (AIF) and a tissue
region of interest was placed over the tumor periphery using semiquantitative AUCmaps
(Fig. 1). The tumor periphery was defined as the 3 mm outer rim of the tumor, as a representa-
tive region of viable tumor tissue less affected by elevated interstitial pressure and necrosis
most present in the tumor center [28]. Signal intensity versus time curves (Fig. 2) were ex-
tracted for the AIF and the tumor tissue ROI and tracer concentrations were approximated in
accordance to their relative enhancement (S/S0–1, where S is signal intensity and S0 is the signal
intensity before arrival of the contrast agent). A two-compartment exchange model [29,30]
was fitted to the MRI data and generated three independent model parameters: tumor plasma
flow PF (mL/100mL/min), as a measure of tumor perfusion, tumor plasma volume PV (%), as
a parameter of tumor vascularity, permeability-surface area product PS (mL/min/100 mL), as a
Fig 1. Representative axial TWISTMR images of a rat with a subcutaneous colon carcinoma xenograft
over the left lateral flank after 7 days of regorafenib therapy.Note the hypointense tumor center
corresponding to areas of beginning or present tumor necrosis and consecutively altered contrast media
kinetics. For the assessment of tumor microcirculation a donut-shaped region-of-interest (red area) was
drawn over vital tumor areas of the tumor periphery using semiquantitative AUCmaps.
doi:10.1371/journal.pone.0115543.g001
Fig 2. Representative signal-intensity vs. time curve for the assessment of contrast media kinetics in
the tumor (red) and the inferior vena cava (blue).
doi:10.1371/journal.pone.0115543.g002
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parameter of tumor endothelial permeability and the tumor interstitial volume VE (%). Addi-
tionally ΔPF (PF-Baseline—PF-Follow-up), ΔPV (PV-Baseline—PV-Follow-up), PS (PS-base-
line—PS-follow-up) and ΔTTB (TTB-baseline—TTB-follow-up) were calculated.
18F-FDG-PET
Small-animal PET was performed on a preclinical microPET scanner (Inveon, Siemens Health-
care AG, Erlangen, Germany). Each animal was placed in prone position inside a custom-built
acrylic glass-imaging chamber for hygienic reasons and to allow for regulated anesthesia deliv-
ery. 60 min after manual intraperitoneal injection of 18F-FDG (50 MBq; ~500 μL), list-mode
PET data were acquired for 30 min (15 min emission, 15 min transmission). Images were re-
constructed using OSEM 3D algorithm with 128 x 128 matrix. All data were processed with an
Inveon AcquisitionWorkplace (Siemens Healthcare, Erlangen, Germany). OSEM 3D image re-
construction algorithm was used as implemented in the software from the manufacturer. PET
images were analyzed using Vinci 4.07 (http://www.nf.mpg.de/vinci3/). Maximum tumor up-
take was measured in a corresponding tumor ROI over the tumor periphery in axial plane.
Background was determined as mean uptake in a 7 mm diameter circular ROI in the right liver
lobe in axial plane and tumor-to-background ratios (TTB) were calculated accordingly.
Immunohistochemistry
The formaldehyde-fixed and paraffin-embedded tissue was stained with focus on various as-
pects of tumor pathophysiology, specifically microvascular density (CD-31), tumor cell prolif-
eration (Ki-67) and apoptosis (TUNEL). Tissue samples were de-waxed and rehydrated
following standard procedures including pre-heating at 60°C and washing in xylene substitute
(Neo-Clear, Merck KgaA, Darmstadt, Germany) with rehydration in a graded series of ethanol
(100%, 96%, 90% and 70% ethanol) followed by double distilled water. Subsequently, dedicated
staining procedures were initiated.
Ki-67 antigen staining
A Ki-67-specific monoclonal rabbit anti-human antibody (SP6, Abcam ab16667 1:100,
Cambridge, United Kingdom) was used to quantify tumor cell proliferation. The tissue was
de-masked in 1 x citrate buffer (pH = 6.0) (DAKO Diagnostika, Hamburg, Germany) using
microwave irradiation at 600W. After washing the slides in ddH2O and TBS-Tween (0.05%) a
multi-step kit (Dako EnVision+ System HRP (DAB), DAKO Diagnostika, Hamburg, Ger-
many) was used for the staining, following the manufacturer’s instructions. Counterstaining
was performed using Mayer´s Haemalaun (Merck KGaA, Darmstadt, Germany) and the
slides were covered with Kaiser´s Glycerin Gelatine (Merck KgaA, Darmstadt, Germany). Re-
sults were quantified as the average number of proliferating cells in 10 random fields at 200x
magnification.
CD-31 antigen staining
For immunohistochemical assessment of tumor microvascular density, tumor sections were in-
cubated with a polyclonal rabbit anti-CD31 primary antibody (Abcam ab28364 1:50, Cam-
bridge, United Kingdom) overnight. Further work-up of tissue samples was performed using
the EnVision+ System HRP (AEC) (DAKO Diagnostika, Hamburg, Germany) according to
the manufacturer´s instruction. Counterstaining was performed using Mayer´s Haemalaun
(Merck KgaA, Darmstadt, Germany) and slides were covered with Kaiser´s Glycerin Gelatine
(Merck KgaA, Darmstadt, Germany). Tumor microvessels were quantified as previously
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described in the literature [31]. Results were quantified as the average number of endothelial
cells in 10 random fields at 200x magnification.
Statistical analysis
Continuous variables are presented as means with standard deviations. Comparison of MRI
perfusion parameters, PET tumor-to-background-ratio and immunohistochemical values be-
tween the treatment and control group were performed using the Mann-Whitney-U-test. A
Wilcoxon-signed-rank test was applied for intragroup comparisons of MRI perfusion and PET
parameters between baseline (day 0) and follow-up (day 7). Correlations between MRI perfu-
sion and PET TTB as well as between MRI perfusion and immunohistochemistry were evaluat-
ed by Spearman’s correlation coefficients. P-values<0.05 were considered statistically
significant. All analyses were performed with SPSS software for Microsoft Windows (version
21.1, IBM, Armonk, NY).
Results
The experimental protocol, including multimodality imaging and immunohistochemistry was
successfully completed in n = 17 animals. The animals tolerated all procedures well, without
adverse effects noted. At baseline no significant differences in tumor volume were present be-
tween the therapy and the control group. In the therapy group, mean tumor volume did not
change significantly between day 0 (581 ± 131 mm3) and day 7 (780 ± 235 mm3; p>0.05). A
significant increase of tumor volume was observed in the control group between day 0 (235 ±
30 mm3) and day 7 (442 ± 51 mm3; p<0.05).
Perfusion MRI
The two-compartment model fit the data well in all experiments with a representative arterial
input function and a tumor fit. In the regorafenib-treated therapy group plasma flow significant-
ly (p<0.01) declined from 81.1 ± 7.5 mL/100 mL/min at baseline to 50.6 ± 16.0 mL/100 mL/min
at follow-up on day 7. In the control group a significant (p<0.03) increase of plasma flow was
observed from 69.9 ± 14.3 mL/100mL/min on day 0 to 93.1 ± 19.4 mL/100mL/min on day 7. In-
dividual values demonstrated an unidirectional decline of tumor perfusion in the therapy group
and an unidirectional increase in the control group. Mean plasma volume decreased significantly
(p<0.01) over the course of the experiment from 12.1 ± 3.6% at baseline to 7.5 ± 1.6% at follow-
up. In the control group no significant change (p>0.05) of mean plasma volume was observed
between baseline and follow-up (9.4 ± 2.3% to 11.6 ± 3.0%). Individual values for baseline and
follow-up measurements demonstrate an unidirectional decrease of tumor vascularity in ther-
apy group and non-uniform changes in the control group. In the therapy group a significant
(p<0.01) decrease of permeability-surface area product (PS) from 13.6 ± 3.2 mL/100mL/min to
7.9 ± 2.3 mL/100mL/min between baseline and follow-up was observed. In the control group no
significant (p>0.05) changes of the permeability-surface area product were observed (13.0 ±
4.4 mL/100 mL/min to 13.0 ± 4.0 mL/100 mL/min). Individual values also demonstrate an uni-
directional decline of endothelial permeability in therapy group and non-uniform changes in
the control group. Table 1 lists the individual perfusion MRI values for baseline and follow-up
measurements and Fig. 3 the corresponding line diagrams.
18F-FDG-PET
In the regorafenib-treated therapy group 18F-FDG PET tumor-to-background-ratio (TTB) sig-
nificantly (p<0.01) decreased from day 0 (3.4 ± 0.6) to day 7 (1.9 ± 1.1, Fig. 4). In the control
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group TTB increased significantly (p<0.03) from baseline (3.4 ± 1.5) to follow-up (4.7 ± 1.4)
(Fig. 4). Individual values for baseline and follow-up TTB measurements are displayed in
Table 2.
Immunohistochemistry
Significant anti-angiogenic effects of regorafenib were observed in the investigated colon carcino-
ma xenografts with a significantly (p<0.05) lower tumor microvascular density, quantified by
CD-31 stainings, in the regorafenib-treated therapy than in control group (7.0 ± 2.4 vs. 16.1 ± 5.9).
Significant anti-proliferative effects of regorafenib were noted, with a significantly (p<0.03)
lower number of proliferating cells in therapy than in control group (Ki-67, 434.0 ± 62.9 vs.
663.0 ± 98.3). Representative tumor sections with stainings for CD-31 and Ki-67 are displayed in
Fig. 5. Individual values of immunohistochemical stainings are displayed in Table 3.
Table 1. Individual perfusion MRI parameters of tumor microcirculation with tumor plasma flow (mL/100mL/min), plasma volume (%) and
endothelial permeability-surface area product PS (mL/100mL/min) baseline and follow-up in the therapy and the control group.
Animal No. Plasma Flow [mL/100mL/min] Plasma Volume [mL/100mL] Endothelial Permeability-Surface
Area Product PS [mL/100mL/min]
Day 0 Day 7 Delta PF Baseline Day 7 Delta PV Baseline Day7 Delta EF
THERAPY GROUP
1 84.0 53.0 -31.0 18.2 7.0 -11.1 15.5 5.4 -10.2
2 85.3 62.4 -22.9 9.0 7.7 -1.3 14.9 7.2 -7.7
3 69.2 38.1 -31.1 16.1 9.0 -7.1 17.8 6.4 -11.4
4 69.3 23.3 -46.0 12.0 8.2 -3.8 8.9 5.9 -3.0
5 82.5 30.3 -52.2 8.9 6.0 -2.9 14.3 11.5 -2.8
6 82.7 45.6 -37.1 12.0 5.4 -6.6 10.4 5.6 -4.8
7 88.6 70.5 -18.1 6.2 5.2 -1.1 11.1 7.4 -3.6
8 89.4 67.7 -21.7 13.5 10.1 -3.4 11.7 10.9 -0.8
9 85.9 53.6 -32.3 14.1 7.4 -6.7 18.5 10.0 -8.5
10 74.2 61.4 -12.8 11.1 9.1 -2.1 12.4 9.2 -3.2
Mean 81.1* 50.6* -30.5# 12.1* 7.5* -4.6# 13.6* 7.9* -5.6#
SD 7.5 16.0 12.3 3.6 1.6 3.2 3.2 2.3 3.6
CONTROL GROUP
1 40.6 56.2 15.6 6.4 13.5 7.2 8.3 6.7 -1.6
2 72.0 91.4 19.4 9.9 9.8 -0.1 7.1 14.0 7.0
3 67.7 89.7 22.0 9.8 12.8 3.0 17.0 16.5 -0.5
4 74.6 96.7 22.1 7.8 7.4 -0.3 13.2 13.4 0.2
5 87.6 121.7 34.2 12.6 12.3 -0.4 19.0 18.5 -0.4
6 74.7 95.0 20.3 11.8 16.1 4.3 15.1 12.5 -2.6
7 71.9 100.7 28.8 7.8 9.2 1.4 11.5 9.7 -1.8
Mean 69.9** 93.1** 23.2# 9.4 11.6 2.1# 13.0 13.0 0.0#
SD 14.3 19.4 6.3 2.3 3.0 2.8 4.4 4.0 3.2
Note the significant decrease of tumor microcirculatory parameters between day 0 and day 7 (*) as well as between the therapy and the control group (#).
* significant difference (p<0.01) between baseline and follow-up
** significant difference (p<0.03) between baseline and follow-up
# significant difference (p<0.01) between therapy and control group
doi:10.1371/journal.pone.0115543.t001
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Fig 3. Line diagrams of the development of individual values of perfusion MRI parameters of tumor microcirculation in the therapy and the control
group. a. Note the significant (p<0.01) unidirectional decline of tumor plasma flow (mL/100mL/min) in all tumors under regorafenib therapy and a significant
unidirectional increase of tumor perfusion (p<0.03) in untreated control group between baseline (day0) and follow-up (day 7). b. Note the significant (p<0.01)
unidirectional decrease of tumor plasma volume (%) in all tumors of the regorafenib-treated therapy group between day 0 and day 7 as well as non-uniform,
non-significant (p>0.05) changes in control group. c.Note the significant (p<0.01) unidirectional decline of tumor endothelial permeability in all tumors under
regorafenib treatment between baseline and follow-up as well as a non-uniform development of individual values with non-significant (p>0.05) changes of
mean PS in the control group.
doi:10.1371/journal.pone.0115543.g003
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Fig 4. Development of individual values of tumor glucosemetabolism, assessed by PET as tumor-to-
background ratio (TTB), in the therapy and in the control group between baseline and follow-up.Note
the almost unidirectional decline of individual TTB values with a slight increase of TTB in only one tumor of
the regorafenib-treated therapy group as well as a significantly (p<0.01) decreased mean TTB between day
0 and day 7. In the control group a uniform increase of individual TTB values can be observed with a
significant (p<0.03) rise of mean TTB in the untreated colon carcinoma xenografts.
doi:10.1371/journal.pone.0115543.g004
Table 2. Individual PET tumor-to-background (TTB) values in the investigated subcutaneous human
colon carcinoma xenografts at baseline and follow-up in the therapy and in the control group.
Rat No. Tumor-To-Background-Ratio (TTB)
Day 0 Day 7 Delta TTB
THERAPY GROUP
1 4.0 0.9 -3.1
2 3.2 1.3 -2.0
3 4.1 1.6 -2.6
4 2.0 1.4 -0.7
5 3.3 1.2 -2.0
6 3.3 1.4 -1.8
7 3.3 1.7 -1.6
8 3.6 2.3 -1.4
9 3.2 3.7 0.4
10 4.3 4.1 -0.2
Mean 3.4* 1.9* -1.5#
SD 0.6 1.1 1.1
CONTROL GROUP
1 2.5 2.7 0.3
2 3.4 3.7 0.4
3 2.4 3.7 1.3
4 3.1 4.9 1.8
5 1.6 6.4 4.8
6 5.5 5.8 0.4
7 5.4 5.9 0.5
Mean 3.4** 4.7** 1.3#
SD 1.5 1.4 1.6
Note the significant (p<0.01) decrease of tumor TTB between day 0 and day 7 in the therapy group, as
well as the significantly (p<0.01) increased glucose metabolism in the control group on day7.
*significant difference (p<0.01) between baseline and follow-up
** significant difference (p<0.03) between baseline and follow-up
# significant difference (p<0.01) between therapy and control group
doi:10.1371/journal.pone.0115543.t002
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Correlation between MRI perfusion parameters and 18F-FDG-PET
Good to moderate, significant correlations were observed between tumor plasma flow ΔPF
and PET tumor-to-background ratio ΔTTB (r = 0.78; p<0.01) (Fig. 6), between ΔPV and
ΔTTB (r = 0.67; p<0.01) and between ΔPS and ΔTTB (r = 0.75; p<0.01) (Table 4).
Correlation between MRI perfusion parameters and
immunohistochemistry
ΔPF showed moderate, but significant correlations with CD-31, as a marker of tumor micro-
vascular density (r = 0.51; p<0.05) and with Ki-67, as a marker of tumor cell proliferation (r =
0.57; p<0.03). Moderate but significant correlations were also observed between ΔPV and CD-
31-stainings (r = 0.55; p<0.03) and between ΔPV and Ki-67 (r = 0.67; p<0.01), as well as be-
tween ΔPS and CD-31 (r = 0.49; p<0.05) and between ΔPS and Ki-67 (r = 0.57; p<0.03)
(Table 5).
Correlation between 18F-FDG-PET parameters and
immunohistochemistry
Modest, but significant correlations were observed between ΔTTB and CD-31 (r = 0.51;
p<0.05), as well as between ΔTTB and Ki-67 stainings (r = 0.56; p<0.03) (Table 6).
Discussion
The present study evaluated the potential of functional imaging biomarkers of therapy re-
sponse using a multimodality imaging protocol with perfusion MRI and 18F-FDG-PET for the
non-invasive monitoring of regorafenib therapy effects on experimental colorectal carcinoma
xenografts in rats. Results demonstrated that the multiparametric MRI/PET imaging protocol
allowed for the early detection of regorafenib effects by measuring significant changes of tumor
microcirculation and glucose metabolism under therapy (Fig. 7). In accordance with these re-
sults, immunohistochemistry revealed a significant reduction of tumor microvascular density
Fig 5. Representative tumor sections of human colon carcinoma xenografts with immunohistochemical
stainings for tumor cell proliferation (Ki-67) and tumormicrovascular density (CD-31) for the regorafenib-
treated therapy (left column) and the control group (right column) ex vivo.Note the significantly (p<0.03)
lower number ofKi-67-positive, proliferating cells (stained in brown) in the therapy group, consistent with anti-
proliferative effects of regorafenib, as well as the significantly (p<0.03) higher number of CD-31-positive
endothelial cells (stained in brown) in the untreated control group, consistent with anti-angiogenic effects of
regorafenib.
doi:10.1371/journal.pone.0115543.g005
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and tumor cell proliferation under regorafenib therapy. Quantitative changes of tumor micro-
circulatory parameters showed significant correlations with changes of tumor glucose metabo-
lism and with immunohistochemical parameters of tumor vascularity and tumor cell
proliferation. These results support our hypothesis that perfusion MRI and 18F-FDG-PET
could be clinically applicable for generating non-invasive imaging biomarkers for monitoring
early changes in tumor pathophysiology under molecular cancer therapies.
Perfusion MRI
During a one-week treatment protocol with regorafenib, a significant decrease of tumor perfu-
sion, tumor vascularity and tumor permeability was observed, whereas a significant increase of
tumor perfusion was detected in the control group. These results are in accordance with several
pre-clinical and clinical studies in the literature [32–34], including Padhani et al who reported
that tumor plasma flow quantified by dynamic, contrast-enhanced (DCE-) MRI decreased sig-
nificantly following a one-week treatment protocol with the multityrosine kinase inhibitor sor-
afenib in an experimental model of breast carcinoma in mice [35]. The uni-directional decrease
Table 3. Individual values for the investigated immunohistochemical parameters of tumor
microvascular density (CD-31) and tumor cell proliferation (Ki-67) in the therapy and control group.
Therapy Group























Note the significantly reduced tumor vascularity and tumor cell proliferation in the regorafenib-treated
therapy group.
* significant difference (p<0.03) between therapy and control group
** significant difference (p<0.03) between therapy and control group
doi:10.1371/journal.pone.0115543.t003
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of all individual values of tumor microcirculation, including plasma flow, plasma volume and en-
dothelial permeability surface area product, under regorafenib therapy is in support of our hy-
pothesis that in the current experimental setting MRI parameters of tumor microcirculation can
be reliably applied as non-invasive imaging biomarkers of therapy response to molecular cancer
therapies in vivo. With regard to clinical translation, however, major unsolved issues still exist, as
a reproducible assessment of quantitative parameters of tissue microcirculation using perfusion
imaging is strongly dependent on standardized protocols of data acquisition and post-processing
[3,36–39]. The lack of harmonization in perfusion imaging data acquisition and post-processing
between imaging centers can be regarded as the prime obstacle for the broad implementation of
functional perfusion MRI imaging into clinical practice over the last years. Although multiple ini-
tiatives have attempted, no broadly accepted consensus was reached so far.
18F-FDG-PET
In the same experimental sessions, concurrent 18F-FDG PET examinations were performed to
acquire functional information on tumor glucose metabolism in the investigated colon carcino-
ma xenografts and to evaluate potential effects of the multityrosine kinase inhibitor regorafenib
on 18F-FDG tumor-to-background ratio between liver and vital tumor tissue, a well-proven
Fig 6. Representative line regression analysis for Spearman’s correlation coefficient between tumor
plasma flow (ΔPF, mL/100mL/min) and tumor glucosemetabolism (ΔTTB). Note the good and
significant correlation between ΔPF and ΔTTB (r = 0.78, p<0.01) for the values of the therapy and the
control group.
doi:10.1371/journal.pone.0115543.g006
Table 4. Moderate to good and highly significant correlations between perfusion MRI parameters of
tumor microcirculation including tumor plasma flow (ΔPF), tumor plasma volume (ΔPV) the tumor
endothelial surface area product (ΔPS) with PET ΔTTB.
Correlation Spearman r p
ΔPF/ΔTTB 0.78* < 0.01
ΔPV/ΔTTB 0.67* < 0.01
ΔPS/TTB 0.75* < 0.01
*significant correlations
doi:10.1371/journal.pone.0115543.t004
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surrogate parameter of glucose metabolism. [40–42]. Quantitative assessments of tumor
glucose metabolism using 18F-FDG-PET can be used as a surrogate endpoint to determine
early treatment efficacy in established primarily cytotoxic tumor therapies (e.g. chemotherapy,
radiotherapy) and novel molecular cancer therapies alike [41]. Kristian et al. reported in a
study investigating triple-negative breast cancer xenografts in mice that 18F-FDG-PET can be
applied for the assessment of therapy effects of the anti-VEGF antibody bevacizumab as early
as 24h after first treatment [42]. In our study, a significant decrease of 18F-FDG tumor-to back-
ground ratio was observed in therapy group, while a significant increase of tumor glucose me-
tabolism was detected in the untreated control group. Intraindividual comparisons of tumor
18F-FDG TTB and perfusion MRI parameters revealed good and significant correlations for
the therapy and the control group. These findings are in accordance with Meier et al who re-
ported in an experimental study of rhabdomyosarcoma xenografts under anti-angiogenic treat-
ment that perfusion MRI parameters of tumor microcirculation showed correlations with
glucose metabolism acquired by 18F-FDG PET [43]. The authors concluded that the correlating
decrease of tumor microcirculation and glucose metabolism under treatment was most likely
due to reduced tissue perfusion and tumor metabolism in early occurring pre-necrotic tumor
areas.
A multimodality, multiparametric imaging protocol combining morphological and func-
tional MRI with 18F-FDG-PET offers a comprehensive, multifaceted non-invasive characteri-
zation of the tumor microenvironment in vivo yielding information on microvascular and
metabolic changes under treatment [17,44]. The acquisition of functional information on
tumor microcirculation and glucose metabolism complements high-resolution morphological
imaging of tumors with perspectives not only for early therapy monitoring, but also for pre-
therapeutic treatment stratification of patients and evaluation of tumor heterogeneity in inten-
sity modulated radiotherapy [45–47]. Additionally, the complementary information may
Table 5. Modest, but significant correlations between perfusion MRI parameters of tumor
microcirculation and immunohistochemical markers of tumor microvascular density (CD-31) and
tumor cell proliferation (Ki-67).
Correlation Spearman r p
ΔPF/CD-31 0.51* < 0.05
ΔPF/Ki-67 0.57* < 0.03
ΔPV/CD-31 0.55* < 0.03
ΔPV/Ki-67 0.67* < 0.01
ΔPS/CD-31 0.49* < 0.05
ΔPS /Ki-67 0.57* < 0.03
*significant correlations
doi:10.1371/journal.pone.0115543.t005
Table 6. Moderate, but significant correlations between PET tumor-to-background ratio (ΔTTB) and
immunohistochemical markers of tumor microvascular density (CD-31) and tumor cell proliferation
(Ki-67).
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provide a higher level of confidence for the stratification of therapy responders from non-re-
sponders in situations where the PET or MRI data alone is inconclusive. However, the combi-
nation of both modalities complicates the implementation of integrated imaging protocols and
may be less feasible in clinical routine, also in the light of protocol length and examination
time. Additionally challenges exist with regard to the implementation of standardized imaging
protocols for MRI and PET, a problem that still remains unsolved for perfusion MRI data ac-
quisition and analysis, but also present in PET where semi-quantitative SUVmax values are de-
pendent on scanner type, detectors or acquisition protocol. The advent of integrated hybrid
MRI/PET scanners to patient care will have to prove if routine examinations investigating
functional information from both modalities significantly enhance diagnostic accuracy.
Immunohistochemical validation
Immunohistochemical analysis revealed significant anti-angiogenic and anti-proliferative ef-
fects of regorafenib on colorectal carcinoma xenografts. In the treatment group the decrease of
plasma flow,plasma volume and endothelial permeability correlated moderately, but signifi-
cantly with a decline in microvascular density and tumor cell proliferation quantified by immu-
nohistochemistry. The observed correlations between tumor microcirculation and
immunohistochemical parameters of tumor pathophysiology may be explained by reduced tis-
sue perfusion in pre-necrotic tumor areas [48] and a regress of the fraction of tumor vessels in
Fig 7. Representative axial images of the investigated human colon carcinoma xenografts including
tumor morphology (T2w images, top row), tumor perfusion parameter maps (middle row) and 18F-
FDG-PET (bottom row) before therapy (left column) and after a one-week treatment course of
regorafenib (right column).Note the significant decrease of tumor plasma flow (mL/100mL/min) and tumor
glucose metabolism (TTB) after regorafenib therapy between baseline and follow-up. The hyperintense
central tumor regions on the T2-weighted image after therapy are consistent with increasing, therapy-induced
tumor necrosis.
doi:10.1371/journal.pone.0115543.g007
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the early stages of the treatment period [25]. Contrarily, Atkin and co-workers reported a para-
doxical negative correlation between tumor microcirculatory parameters quantified by perfu-
sion MRI and immunohistochemical assessments of tumor microvascular density (CD-31) in
patients with rectal adenocarcinoma [49]. The reason for these variable results may be a lack of
standardization with a large variety in MRI data acquisition and analysis protocols as well as
immunohistochemical techniques. Although the observed correlations between perfusion MRI
and immunohistochemistry in our study were only moderate, the results of our study are in
support of our hypothesis that the investigated parameters of tumor microcirculation directly
reflect processes of tumor pathophysiology and are therefore applicable as non-invasive imag-
ing biomarkers of therapy response.
Our results are limited in several aspects. First, our multimodality imaging protocol was im-
plemented on separate PET and MRI scanners. Although the time between both examinations
was kept to a minimum in our study, an integrated imaging protocol on a hybrid MRI/PET
scanner with synchronous acquisition of both parameters may offer higher data stability and
broadened concordance between MRI and PET parameters due to leveled experimental condi-
tions. Our study investigated only one tumor-therapy-combination in a heterotopic xenograft
model of colon cancer with only limited translational relevance to orthotopic tumor patho-
physiology in humans. For validation purposes of imaging results, only a small scope of immu-
nohistochemical stainings were investigated with significant, but only moderate correlations to
the acquired MRI parameters of tumor microcirculation. Nevertheless the selected immunohis-
tochemical parameters can be considered representative for central aspects of tumor patho-
physiology under molecular cancer therapy.
In conclusion, our results indicate that a multimodal, multiparametric perfusion MRI / PET
imaging protocol allows for the early and reliable assessment of regorafenib therapy effects in
the investigated experimental model of colorectal adenocarcinoma. Study results add further
support to the hypothesis of a present biological relationship between functional parameters of
tumor microcirculation and tumor cell glucose metabolism by the observed significant correla-
tions between perfusion MRI and 18F-FDG-PET data. Beyond the individualized applicability
of the parameters as imaging biomarkers of therapy response to molecular cancer treatments,
the investigated multimodal, multiparametric perfusion MRI / PET imaging protocol offers a
comprehensive, multi-faceted and non-invasive characterization of the tumor microenviron-
ment in vivo. However, clinical investigations on integrated hybrid MRI/PET scanners will
have to prove if routine examinations investigating functional information from both modali-
ties significantly enhance diagnostic accuracy in patient care.
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